Description

Ulcavis (bismuth subcitrate) Coated Tablets 120 mg. №112

Ingredients

Each coated tablet contains 120 mg of bismuth subcitrate.

Dosage

The recommended dosage is one tablet to be taken orally three times a day, or as directed by a healthcare professional.

Indications

Ulcavis tablets are indicated for the treatment of Helicobacter pylori infection and associated gastritis.

Contraindications

Do not use Ulcavis tablets if you are allergic to bismuth subcitrate or any other ingredients in the product.

Directions

Swallow the tablet whole with water. Do not crush or chew the tablet.

Scientific Evidence

Bismuth subcitrate, the active ingredient in Ulcavis tablets, has been extensively studied for its efficacy in treating Helicobacter pylori infections. Research has shown that bismuth subcitrate helps to eradicate the bacteria and reduce inflammation in the stomach lining, leading to improved symptoms and healing of ulcers.

Additional Information

Ulcavis tablets have been shown to be well-tolerated with minimal side effects, making them a safe and effective option for the treatment of H. pylori infections. It is important to complete the full course of treatment as prescribed by your healthcare provider to ensure the best possible outcome.

Studies have also indicated that bismuth subcitrate may have additional benefits beyond its anti-bacterial properties, including anti-inflammatory effects and mucosal protection in the gastrointestinal tract. These mechanisms contribute to the overall healing process and symptom relief in patients with gastritis and ulcers.